All In MedTech

FDA Clearance Tracker · P010032-S189

Prodigy, Proclaim, and Proclaim XR Spinal Cord Stimulation (SCS) Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 24, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 24, 2023

Approved

Time to decision

193 days

Received Jul 15, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P010032-S189
Device name
Prodigy, Proclaim, and Proclaim XR Spinal Cord Stimulation (SCS) Systems
Applicant location
Plano, TX
Received
Jul 15, 2022
Decided
Jan 24, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010032

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for expanding the indications to include diabetic peripheral neuropathy (DPN) of the lower extremities for the tonic stimulation mode.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.